Skip to main content
SpringerLink
Log in

A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model

  • Published:
Angiogenesis Aims and scope Submit manuscript

Abstract

Vascular endothelial growth factor (VEGF) is a primary stimulant of tumor angiogenesis. We previously raised a neutralizing anti-VEGF monoclonal antibody 2C3 that blocks the interaction of VEGF with VEGFR2 (KDR/Flk-1) but not with VEGFR1 (FLT-1/flt-1). Here, we describe the therapeutic effects of 2C3 on tumor growth in an orthotopic model of MDA-MB-231 human breast carcinoma implanted in the mammary fat pads (MFP) of nude mice. Administration of 2C3 to mice with 100–150 mm3 tumors inhibited tumor growth by 75%, as compared to recipients of the isotype-matched irrelevant control IgG, C44. Treatment with 2C3 also inhibited the establishment of tumor colonies and reduced tumor burden in the lungs of mice injected intravenously with MDA-MB-231 cells. No toxicity was observed in these studies. The mean microvascular density (MVD) of tumors in 2C3-treated mice was 55 ± 5 per mm2, as compared to 188 ± 5 per mm2 in the C44-treated control group. The decrease in MVD closely correlated with the degree of inhibition of tumor growth. Treated tumors mostly contained mid-size and large vessels. Microvessels were mainly confined to the peripheral layer of tumor that bordered on the normal MFP epithelium. Tumor vessels had decreased expression of VEGFR2, indicating that neutralization of tumor-derived VEGF by 2C3 down-regulates the expression of VEGFR2 on tumor vasculature. This, in turn, may limit re-initiation of angiogenesis by either tumor-derived or stromal VEGF. These findings suggest that 2C3 is a candidate for treating primary cancer and for preventing the outgrowth of tumor metastases in cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182–6.

    Google Scholar 

  2. Algire GH, Chalkley HW, Legallais FY, Park HD. Vascular reactions of normal and malignant tumors in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 1945; 6: 73–85.

    Google Scholar 

  3. Gimbrone MA, Jr, Cotran R, Leapman S, Folkman J. Tumor growth and neovascularization: An experimental model using rabbit cornea. J Natl Cancer Inst 1974; 52: 413–27.

    Google Scholar 

  4. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4–6.

    Google Scholar 

  5. Fidler IJ. Angiogenesis and cancer metastasis. Cancer J Sci Am 2000; 6 (Suppl 2): S134–41.

    Google Scholar 

  6. Fidler IJ, Rumar R, Bielenberg DR, Ellis LM. Molecular determinants of angiogenesis in cancer metastasis. Cancer J Sci Am 1998; 4: S58–66.

    Google Scholar 

  7. McNamara DAA, Harmey JH, Walsh TN et al. Significance of angiogenesis in cancer therapy. Br J Surg 1998; 85: 1044–55.

    Google Scholar 

  8. Brown LF, Berse B, Jackman RW et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Human Path 1995; 1: 86–91.

    Google Scholar 

  9. Warren RS, Yuan H, Matli MR et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95: 1789–97.

    Google Scholar 

  10. Boocock CA, Charnock-Jones DS, Sharkey AM. Expression of vascular endothelial growth factor and its receptors FLT and KDR in ovarian carcinoma. J Natl Cancer Inst 1995; 87: 506–16.

    Google Scholar 

  11. Berkman RA, Merrill MJ, Reinhold WC et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 1993; 91: 153–9.

    Google Scholar 

  12. Connolly DT, Heuvelman DM, Nelson R et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84: 1470–8.

    Google Scholar 

  13. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851–8.

    Google Scholar 

  14. Gospodarowicz D, Abraham JA, Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced y pituitary-derived folliculo stellate cells. Proc Natl Acad Sci USA 1989; 86: 7311–5.

    Google Scholar 

  15. Keck PJ, Hauser SD, Krivi G et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309–12.

    Google Scholar 

  16. Leung DW, Cachianes G, Kuang W-J et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306–9.

    Google Scholar 

  17. Conn G, Bayne ML, Soderman DD et al. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci USA 1990; 87: 2628–32.

    Google Scholar 

  18. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endo Rev 1992; 13: 18–32.

    Google Scholar 

  19. Senger DR, Vandewater L, Brown LF et al. Vascular permeability factor (VPF,VEGF) in tumor biology. Cancer Meta Rev 1993; 12: 303–24.

    Google Scholar 

  20. Dvorak HF, Sioussat TM, Brown LF et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors-concentration in tumor blood vessels. J Exp Med 1991; 174: 1275–8.

    Google Scholar 

  21. Klement G, Baruchel S, Rak J et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15–24.

    Google Scholar 

  22. Bruns CJ, Liu W, Davis DW et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 2000; 89: 488–99.

    Google Scholar 

  23. Tran J, Rak J, Sheehan C et al. Marked induction of the IAP family antiapoptotic proteins surviving and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 1999; 264: 781–8.

    Google Scholar 

  24. Meyer M, Clauss M, Lepple-Wienhues A et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 1999; 18(2): 363–74.

    Google Scholar 

  25. Fuh G, Garcia KC, de Vos AM. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem 2000; 275(35): 26690–5.

    Google Scholar 

  26. Ahmed A, Dunk C, Kniss D, Wilkes M. Role of VEGF receptor-1 (FLT-1) in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells. Lab Invest 1997; 76(6): 779–91.

    Google Scholar 

  27. Siemeister G, Martiny-Baron G, Marme D. The pivotal role of VEGF in tumor angiogenesis: Molecular facts and therapeutic opportunities. Cancer Metastasis Rev 1998; 17: 241–8.

    Google Scholar 

  28. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841–4.

    Google Scholar 

  29. Asano K, Yukita A, Matsumoto T et al. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma 1998; 17: 185–90.

    Google Scholar 

  30. Borgstrom P, Bourdon MA, Hillan KJ et al. Neutralizing antivascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998; 35: 1–10.

    Google Scholar 

  31. Asano M, Yukita A, Suzuki H. Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn J Cancer Res 1999; 90: 93–100.

    Google Scholar 

  32. Gerber H-P, Kowalski J, Sherman D et al. Complete inhibition of rabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000; 60: 6253–8.

    Google Scholar 

  33. Soh EY, Eigelberger MS, Kim KJ et al. Neutralizing vascular endothelial growth factor activity inhibits thyrpid cancer growth in vivo. Surgery 2000; 128: 1059–65.

    Google Scholar 

  34. Sledge GW, Jr, Miller K, Novotny W et al. A phase II trial of single-agent rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients within relapsed metastatic breast cancer. Proc Am Soc Clin Oncol 2000; 19: 3a.

    Google Scholar 

  35. Bergsland E, Fehrenbacher L, Meropol NJ et al. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5–fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastic colorectal cancer. Proc Am Soc Clin Oncol 2000; 19: 939.

    Google Scholar 

  36. DeVore RF, Fehrenbacher L, Herbst RS et al. A randomized phase II trial comparing rhumab VEGF (Recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 2000; 19: 485a (Abstr 1896).

    Google Scholar 

  37. Gordon MS, margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843–50.

    Google Scholar 

  38. Brekken RA, Huang X, King S, Thorpe PE. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 1998; 58: 1952–9.

    Google Scholar 

  39. Brekken RA, Overholser J, Stastny VA et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000; 60: 5117–24.

    Google Scholar 

  40. Leppink DM, Bishop DK, Sedmak DD et al. Inducible expression of an endothelial cell antigen on murine myocardial vasculature in association with interstitial cellular infiltration. Transplantation 1989; 48(5): 874–7.

    Google Scholar 

  41. Rouan SK, Otterness IG, Cunningham AC et al. Reversal of colchicines-induced mitotic arrest in Chinese hamster cells with a colchicines-specific monoclonal antibody. Am J Pathol 1990; 137: 779–87.

    Google Scholar 

  42. Burrows FJ, Watanabe Y, Thorpe PE. A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors. Cancer Res 1992; 52: 5954–62.

    Google Scholar 

  43. Ran S, Gao B, Duffy S et al. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 1998; 58(20): 4646–53.

    Google Scholar 

  44. Benjamin LE, Golijanin D, Itin A et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103(2): 159–65.

    Google Scholar 

  45. Huang X, Gottstein C, Brekken RA, Thorpe PE. Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance. Biochem Biophys Res Commun 1998; 252: 643–48.

    Google Scholar 

  46. Morrow KJ, Unuvar E, King SW, Mleczko JB. Techniques for the production of monoclonal and polyclonal antibodies. In Hayat MA (ed): Colloidal Gold: Principles, Methods, and Applications. Orlando, Florida: Academic Press, 1990; 31–57.

    Google Scholar 

  47. Fidler IJ. Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev 1986; 5: 29–51.

    Google Scholar 

  48. Ahlering TE, Jones PA. A new in vivo model to study invasion and metastasis of a human bladder carcinoma. Cancer Res 1987; 47: 6660–5.

    Google Scholar 

  49. Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorgenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990; 50: 717–21.

    Google Scholar 

  50. Zhang RD, Fidler IJ, Price JE. Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Inv Metastasis 1991; 11: 204–15.

    Google Scholar 

  51. Dunk C, Ahmed A. Vascular endothelial growth factor receptor-2–mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells. Am J Pathol 2001; 158: 265–73.

    Google Scholar 

  52. Yoshiji H, Harris SR, Thorgeirsson U. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 1997; 57(18): 3924–8.

    Google Scholar 

  53. Shen BQ, Lee DY, Gerber H-P et al. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth in vitro. J Biol Chem 1998; 273(45): 29979–85.

    Google Scholar 

  54. Wilting J, Birkenhager R, Eichmann A et al. VEGF121 induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of chorioallantoic membrane. Dev Biol 1996; 176(1): 76–85.

    Google Scholar 

  55. Kremer C, Breier G, Risau W, Plate KH. Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res 1997; 57(17): 3852–9.

    Google Scholar 

  56. Arbiser JL, Larsson H, Claesson-Welsh L et al. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGF 1 and VEGFR-2 in vivo. Am J Pathol 2000; 156(4): 1469–76.

    Google Scholar 

  57. Hart IR, Fidler IJ. Role of organ selectivity in determination of metastatic patterns of B16 melanoma. Cancer Res 1981; 41: 1281–5.

    Google Scholar 

  58. Kalebic T, Garbisa S, Glaser B, Liotta LA. Basement membrane collagen: Degradation by migrating endothelial cells. Science 1983; 221:281–3.

    Google Scholar 

  59. Mori S, Ueda T, Kuratsu S et al. Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-4700 in murine osteosarcoma. Int J Cancer 1995; 6: 148–52.

    Google Scholar 

  60. Fidler IJ, Gersten DM, Hart IR. The biology of cancer invasion and metastasis. Acv Cancer Res 1978; 28: 149–250.

    Google Scholar 

  61. Fidler IJ. Critical factors in the biology of human cancer metastasis: Twenty-eight G.H.A. Clowes Memorial Award Lecture. Cancer Res 1990; 50: 6130–9.

    Google Scholar 

  62. Itakura J, Ishiwati T, Shen B et al. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000; 85: 27–34.

    Google Scholar 

  63. Baek JH, Jang JE, Kang CM et al. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene 2000; 19: 4621–31.

    Google Scholar 

  64. Gordon MS, Margolin KA, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Pharmacol 2000; 19(3): 843–850.

    Google Scholar 

  65. Barleon B, Sozzani S, Zhou D et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87(8): 3336–43.

    Google Scholar 

  66. Akuzawa N, Kurabayashi M, Ohyama Y et al. Zinc finger transcription factor Egr-1 activates Flt-1 gene expression in THP-1 cells on induction for macrophage differentiation. Arterioscler Thromb Vasc Biol 2000; 20(2): 377–84.

    Google Scholar 

  67. Clauss M, Gerlach M, Gerlach H et al. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotesmonocyte migration. J Exp Med 1990; 172(6): 1535–45.

    Google Scholar 

Download references

Author information

Author notes

  1. Wei Zhang

    Present address: Department of Obstetrics and Gynecology, Maryland General Hospital, Baltimore, Maryland, USA

Authors and Affiliations

  1. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA

    Wei Zhang & Philip E. Thorpe

  2. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA

    Sophia Ran, M. Sambade & Xianming Huang

Authors
  1. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sophia Ran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Sambade
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xianming Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Philip E. Thorpe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip E. Thorpe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, W., Ran, S., Sambade, M. et al. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 5, 35–44 (2002). https://doi.org/10.1023/A:1021540120521

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1021540120521

Search

Navigation